Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed Monthly Lucentis for Persistent PED in AMD
NCT02944227Phase 4Completed
- Sponsor
- Seoul National University Hospital
- Start
- Mar 2016
- Primary completion
- Feb 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Seoul National University Hospital. Primary endpoints: Changes of a pigment epithelial detachment (PED) at 6 months and Changes of subretinal fluid (SRF) at 6 months. Started Mar 2016; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02944227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944227.